CYP4F2 polymorphism as a genetic risk factor for major hemorrhagic complications in Chinese patients on warfarin therapy

( views:309, downloads:0 )
Author:
Hong-Juan Wang(Institute of Geriatric Cardiology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China)
Tong Yin(Institute of Geriatric Cardiology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China)
Cong Ma(Institute of Geriatric Cardiology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China)
Jie Yang(Institute of Geriatric Cardiology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China)
Qiang Xu(Institute of Geriatric Cardiology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China)
Yan Zhang(Institute of Geriatric Cardiology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China)
Lei Gao(Institute of Geriatric Cardiology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China)
Bin Xu(Institute of Geriatric Cardiology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China)
Yu-Xiao Zhang(Institute of Geriatric Cardiology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China)
Yang Li(Institute of Geriatric Cardiology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China)
Journal Title:
JOURNAL OF GERIATRIC CARDIOLOGY
Issue:
Volume 09, Issue 02, 2012
DOI:
10.3724/SP.J.1263.2012.04162
Key Word:
CYP4F2;Genetic risk factor;Warfarin;Complications

Abstract:

  • [1]Fihn SD,McDonell M,Martin D,et al.Risk factors for complications of chronic anticoagulation.A multicenter study.Warfarin Optimized Outpatient Follow-up Study Group.Ann Intern Med 1993;118:511–520.
  • [2]Caldwell MD,Awad T,Johnson JA,et al.CYP4F2 genetic variant alters required warfarin dose.Blood 2008;111:4106–4112.
  • [3]Takeuchi F,McGinnis R,Bourgeois S,et al.A genome-wide association study confirms VKORC1,CYP2C9,and CYP4F2 as principal genetic determinants of warfarin dose.PLoS Genet 2009;5:E1000433.
  • [4]McDonald MG,Rieder MJ,Nakano M,et al.CYP4F2 is a vitamin K1 oxidase:An explanation for altered warfarin dose in carriers of the V433M variant.Mol Pharmacol 2009;75:1337–1346.
  • [5]Wadelius M,Chen LY,Lindh JD,et al.The largest prospective warfarin-treated cohort supports genetic forecasting.Blood 2009;113:784–792.
  • [6]Higashi MK,Veenstra DL,Kondo LM,et al.Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.JAMA 2002;287:1690–1698.
  • [7]Aithal GP,Day CP,Kesteven PJ,et al.Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.Lancet 1999;353:717–719.
  • [8]Schwarz UI,Ritchie MD,Bradford Y,et al.Genetic determinants of response to warfarin during initial anticoagulation.N Engl J Med 2008;358:999–1008.
  • [9]Lindh JD,Lundgren S,Holm L,et al.Several-fold increase in risk of overanticoagulation by CYP2C9 mutations.Clin Pharmacol Ther 2005;78:540–550.
  • [10]Limdi NA,McGwin G,Goldstein JA,et al.Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.Clin Pharmacol Ther 2008;83:312-321.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn